Kimberly-Clark is readying concessions to address EU antitrust concerns about its bid for Tylenol maker Kenvue that could help it win approval for the $40 billion deal after a preliminary review, people familiar with the matter said.
Kimberly-Clark is readying concessions to address EU antitrust concerns about its bid for Tylenol maker Kenvue that could help it win approval for the $40 billion deal after a preliminary review, people familiar with the matter said.
Kimberly-Clark announced Monday it’s struck an agreement to buy Kenvue in a deal valued at $48.7 billion that would create a consumer staples giant.
Shares of Kimberly-Clark Corp. fell 3.1% in premarket trading Tuesday, after the parent of consumer brands including Huggies diapers, Kleenex tissues and Scott toilet paper reported third-quarter profit that beat expectations, amid volume and price increases, but sales that fell a bit shy.
Kimberly-Clark said on Wednesday it would reorganize into three business units as the Kleenex tissue maker looks to simplify operations and cut costs.